ClinicalTrials.gg
CompletedNCT06510257Updated Feb 7, 2025

Safety and Efficacy Reconyl for Cough With/Without Sore Throat

A Phase 2 interventional study of Reconyl and Placebo tablet of Reconyl in Cough, sponsored by Dexa Medica Group. Completed at 2 sites in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Dexa Medica Group · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study is a prospective, randomized, double-blind and placebo-controlled study to find out if reconyl may relieve the acute cough with/without sore throat.

Read the detailed description

Reconyl is a mixed extract from 4 Indonesian herbs, Vitex trifolia (Legundi), Zingiber officinale var. Amarum (Jahe Gajah), Abrus precatorius (Saga), and Phaleria macrocarpa (Mahkota Dewa), which have been known traditionally to relieve cough, respiratory congestion, and sore throat.

There will be two parallel groups of 30 subjects per group (a total of 60 subjects) planned to be enrolled in this study.

The investigational product: tablets @ 225 mg of Reconyl. Dose administration: One tablet of Reconyl or Placebo, given 3 times daily, for 3 days.

Eligible subjects will be instructed to perform a daily self-assessment on the cough symptoms over the 3 days of treatment, in the Subject Diary. Subject shall return to the study clinic 3 days ± 24 hours after the first dose, for completion of the subject's participation in the study.

02

Conditions studied

  • Cough

Browse trials for

Keywords

  • Cough with sore throat
  • Cough without sore throat
  • Reconyl
03

In context

Cough

429 studies on the registry are indexed under Cough; 69 are open to participants now.

This study's enrollment of 60 is below the median of 80 across 321 interventional studies indexed under Cough.

Browse Cough studies →

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy men or women aged 18 to 60 years with cough with/without sore throat with a maximum onset of 3 days.
  2. Signing the .

Exclusion criteria

Exclusion Criteria:

  1. Body temperature of > 37.3˚C and/or refuse to follow health protocol for COVID-19
  2. Known to herbal drugs
  3. Pregnant or lactating women
  4. Have received any anti-inflammatory or cough-alleviating drugs within the past 24 hours
  5. Presence of vomiting or diarrhea within the past 24 hours and still ongoing at the start of study
  6. Severe illness, e.g. severe hypertension, any other chronic infections or diseases that may induce cough, such as: pulmonary tuberculosis, gastrointestinal reflux diseases (GERD)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Treatment Group

    1 tablet of Reconyl, 3 times daily

    Drug: Reconyl

  • Placebo comparator
    Control Group

    1 tablet of placebo Reconyl, 3 times daily

    Drug: Placebo tablet of Reconyl

Interventions

  • DrugReconyl

    1 tablet of Reconyl, 3 times daily

    Also known as: HerbaKOF

  • DrugPlacebo tablet of Reconyl

    1 tablet of placebo Reconyl, 3 times daily

06

What researchers measure

Primary outcomes

  1. Cough score

    Scoring will be performed and recorded daily in the Subject Diary at time 0, every night time and before the morning dose. At the End of Study (last visit) will be assessed by the subject and recorded by the Investigator. Cough score: • Day time: 0 = No cough; 1= Transient cough occasionally during the daytime; 2 = Frequent cough mildly affecting daily life; 3 = Frequent cough severely affecting daily life. • Night time: 0 = No cough; 1= Transient cough before sleep or occasional cough during the night; 2 = Cough mildly affecting night sleep; 3 = Cough severely affecting night sleep.

    Time frame: Day 0, Day 1, Day 2, Day 3

  2. Visual Analogue Scale (VAS)

    Visual Analogue Scale (VAS) for sore throat (0 - 100), with 0 indicates asymptomatic and 100 refers to the most serious or severe symptom. VAS will be assessed and recorded daily in Subject Diary at time 0, every night time and before the morning dose. At the End of Study (last visit) will be assessed by the subject and recorded by the Investigator.

    Time frame: Day 0, Day 1, Day 2, Day 3

  3. Adverse events

    Any adverse events (AE) and serious adverse events (SAE) will be observed throughout the study conduct.

    Time frame: Day 0, Day 1, Day 2, Day 3

07

Study locations

2 sites
  • Imeri Fkui
    Jakarta Pusat, DKI Jakarta 10430, Indonesia
  • Klinik Satelit Makara UI Depok
    Depok, Jawa Barat, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Sep 2024, 2 months.

Of 21 phase 2 interventional studies under Cough, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 19, 2024
StartActual
Jul 23, 2024
Primary completionActual
Sep 30, 2024
CompletionActual
Oct 3, 2024
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06510257
Lead sponsor
Dexa Medica Group
Collaborators
Fakultas Kedokteran Universitas Indonesia
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Jul 23, 2024
Primary completion
Sep 30, 2024
Completion
Oct 3, 2024
Last update
Feb 7, 2025

Study contacts

Dewi S Rosdiana, Dr,MD,MKes
principal investigator · Department Pharmacology & Therapeutics Faculty of Medicine Universitas Indonesia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion